Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of MRSA infection: a health-care system perspective

von Dach, E.; Morel, C. M.; Murthy, A.; Pagani, L.; Macedo-Vinas, M.; Olearo, F.; and Harbarth, S. (2017) Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of MRSA infection: a health-care system perspective Clinical Microbiology and Infection, 23 (9). pp. 659-666. ISSN 1198-743X
Copy

To date few industry-independent studies were conducted to compare the relative costs and benefits of drugs to treat MRSA infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies -- linezolid versus trimethoprim-sulfamethoxazole plus rifampicin -- for the treatment of MRSA infection.
Item Type Article
Keywords Cost-effectiveness; MRSA infection; trimethoprim-sulfamethoxazole; rifampicin; linezolid; QALYs
Departments Social Policy
LSE Health
DOI 10.1016/j.cmi.2017.02.011
Date Deposited 01 Mar 2017 18:15
URI https://researchonline.lse.ac.uk/id/eprint/69613

Explore Further

picture_as_pdf
subject
Accepted Version
Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 4.0
Download

Atom BibTeX OpenURL ContextObject in Span OpenURL ContextObject Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation METS MODS RIOXX2 XML Reference Manager Refer ASCII Citation
Export

Downloads